February 4, 2021
Fairness for Rx Drug Consumers
Learn How West Virginia Can Address Unfair Rx Drug Price Increases
Webinar featuring National Experts
Moderated by Delegate Matthew Rohrbach (R - Cabell, 17)
Barry Glassman (R), County Executive, Hartford County, Maryland. Executive Glassman was a key champion for Maryland’s Prescription Drug Affordability Board. The Board is charged with reviewing the rising cost of prescription drugs and making recommendations to the Maryland General Assembly on how they can be made more affordable.
Jane Horvath, founder of the Center for Drug Pricing at the National Academy for State Health Policy (NASHP). Ms. Horvath has held research positions with Georgetown University Health Policy Institute, Johns Hopkins University, and MACPAC. Ms. Horvath spent ten years at Merck working on coverage and reimbursement policies in federal programs. She has worked for the Medicaid Directors, the US Senate Finance Committee, and was a Deputy Assistant Secretary for Legislation (Health) at the US Department of Health and Human Services.
Sarah K. Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER). ICER publishes an annual list of Rx drug “Unsupported Price Increases.”
ICER’s 2020 report will focus on up to 13 prescription drugs that experienced the most significant price increase in the U.S. over a one-year period and had the most significant budget impact on the U.S. health system.